The strong revenue beat and accelerating system installations are positive signals for top-line growth, but the sharp decline in profitability and negative operating cash flow are concerning. Traders should watch for the Q3 2026 report to see if the R&D spending surge translates into regulatory milestones (FDA/CE mark) and if gross margins can stabilize. The stock may trade on the revenue beat in the near term, but the bearish profit trends cap upside.
Price Chart
Executive Summary
SS Innovations reported Q2 2026 revenue of $13.9M, up 39.4% YoY, beating the $11.7M consensus estimate. However, the company swung to a net loss of $2.7M from a near-breakeven quarter a year ago, driven by a sharp increase in R&D spending. Gross margin contracted to 50.9% from 59.1%, and operating cash flow remained negative. The strong revenue beat is offset by deteriorating profitability and cash burn, making the overall read mixed.
Key Financial Metrics
Key Facts
- Revenue of $13.9M beat the $11.7M consensus estimate.
- Revenue grew 39.4% YoY, driven by a 40.8% increase in system sales.
- Net loss of $2.7M vs. a net loss of $0.3M in Q2 2025, a significant deterioration.
- Gross margin fell to 50.9% from 59.1% in the prior year quarter.
- R&D expense surged to $2.4M from $0.5M, a 381% increase YoY.
- Operating cash flow was negative $6.5M in H1 2026, improving from negative $9.6M in H1 2025.
- SSi Mantra installations totaled 30 in Q2, up 30.4% YoY, with a cumulative installed base of 224.
- Cash and cash equivalents stood at $13.6M as of June 30, 2026.
- Long-term debt remains at $0.
- FDA 510(k) review for SSi Mantra expected to complete by end of Q1 2027; CE marking expected by end of 2026.
Financial Impact
Revenue beat consensus by ~18.8% ($13.9M vs $11.7M), but net loss widened by $2.4M YoY.
Risk Factors
- Profitability deterioration: Net loss widened significantly despite revenue growth.
- Gross margin compression: 50.9% vs 59.1% YoY, indicating potential pricing pressure or cost inflation.
- Cash burn: Negative operating cash flow of $6.5M in H1 2026, though improved from prior year.
- Regulatory dependence: Stock is highly sensitive to FDA 510(k) and CE marking timelines for the SSi Mantra.
- Dilution risk: Share count increased to 200.2M from 194.2M at year-end 2025 due to a March 2026 private placement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-088726 |
| Document: ea0301887-8k_ssinnova.htm | 0001213900-26-088726 |
| Document: 0001213900-26-088726-index-headers.html | 0001213900-26-088726 |
| Document: 0001213900-26-088726-index.html | 0001213900-26-088726 |
| Document: 0001213900-26-088726.txt | 0001213900-26-088726 |
| 8-K Data (Synthetic) | 0001213900-26-088726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Oct 13, 2026 13d ago | 8-K | $2.55 $2.54 | ▼ −0.39% | ▲ +0.76% | $2.37 (−7.06%) |
Oct 13, 2026 13d ago | 8-K | $2.55 $2.54 | ▲ +0.39% | ▼ −0.76% | $2.37 (+7.06%) |
Oct 9, 2026 17d ago | 424B5 | $2.55 $2.45 | ▲ +3.92% | ▲ +2.43% | $2.37 (+7.06%) |
Oct 5, 2026 21d ago | 8-K | $2.77 $2.55 | ▼ −7.94% | ▼ −8.36% | $2.37 (−14.44%) |
Sep 10, 2026 6w ago | 8-K | $3.30 $3.26 | ▼ −1.21% | ▼ −0.71% | $2.37 (−28.18%) |
Aug 13, 2026 10w ago | 8-K | $3.83 $3.61 | ▼ −5.74% | ▼ −3.78% | $2.37 (−38.12%) |
Jul 17, 2026 14w ago | 8-K | $3.64 $3.57 | ▼ −1.92% | ▼ −1.24% | $2.37 (−34.89%) |
Jul 14, 2026 14w ago | 8-K | $3.67 $3.75 | ▲ +2.18% | ▲ +3.48% | $2.37 (−35.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers